Quanterix (NASDAQ:QTRX) Releases Earnings Results, Beats Expectations By $0.12 EPS

Quanterix (NASDAQ:QTRX) posted its quarterly earnings data on Wednesday. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.12, Zacks reports. Quanterix had a negative net margin of 71.86% and a negative return on equity of 23.92%. The company had revenue of $35.90 million for the quarter, compared to analyst estimates of $36.84 million.

Here are the key takeaways from Quanterix’s conference call:

• Quanterix is increasing investment in its Alzheimer’s diagnostics business, hiring a new diagnostics leader, expanding lab infrastructure, pursuing FDA clearance for LucentAD Complete in H2 2026, and announcing a partnership with Tempus AI to integrate ordering into select EHRs.
• The company reported $36.4 million in Q1 revenue (reported +20% YoY but organic revenue declined 21%), with instrumentation sales softer than expected, 16 Simoa and 11 spatial placements, and pharma revenue down ~33% while academia represented ~65% of Q1 sales.
• Management says it has delivered the $85 million of annualized Akoya cost synergies, maintained >50% non-GAAP gross margin, narrowed adjusted EBITDA loss to $9.8 million, and ended the quarter with $102.6 million in cash and no debt while targeting cash-flow breakeven in the second half of 2026.
• Leadership is shifting from integration to growth and has launched commercial effectiveness initiatives—adding lead-generation reps, market development leaders, leveraging Thermo Fisher distribution, and prioritizing an HD‑X upgrade (with an IVD filing planned in 2027) and Simoa1 early-access feedback to drive second-half revenue.
• The company changed its accounting classification for shipping and handling into cost of goods sold (affecting GAAP gross margin presentation but not non-GAAP margins) and reiterated full‑year 2026 revenue guidance of $169 million–$174 million.

Quanterix Trading Up 2.9%

NASDAQ QTRX traded up $0.08 on Friday, hitting $2.83. 2,359,120 shares of the company were exchanged, compared to its average volume of 1,158,731. Quanterix has a 12 month low of $2.56 and a 12 month high of $8.77. The company has a market cap of $133.32 million, a PE ratio of -1.20 and a beta of 1.15. The stock has a fifty day moving average of $4.11 and a 200-day moving average of $5.60.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on QTRX. Canaccord Genuity Group cut their target price on shares of Quanterix from $8.00 to $4.00 and set a “hold” rating on the stock in a research note on Monday, April 20th. TD Cowen cut their target price on shares of Quanterix from $7.00 to $4.00 and set a “hold” rating on the stock in a research note on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Quanterix in a research note on Tuesday, April 21st. Finally, Wall Street Zen lowered shares of Quanterix from a “hold” rating to a “sell” rating in a research note on Saturday, April 18th. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Quanterix currently has an average rating of “Reduce” and an average price target of $4.00.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd bought a new position in shares of Quanterix in the fourth quarter valued at $27,000. Quarry LP lifted its stake in shares of Quanterix by 277,300.0% in the third quarter. Quarry LP now owns 5,548 shares of the company’s stock valued at $30,000 after buying an additional 5,546 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of Quanterix in the fourth quarter valued at $75,000. HUB Investment Partners LLC bought a new position in shares of Quanterix in the second quarter valued at $81,000. Finally, HRT Financial LP bought a new position in shares of Quanterix in the fourth quarter valued at $82,000. 86.48% of the stock is owned by institutional investors.

About Quanterix

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.